Nuvectis Pharma, Inc. — Q3 2022 Form 10-Q
Reporting period: Three and nine months ended September 30, 2022. Financial statements are unaudited. Nuvectis is a pre-revenue biopharmaceutical company developing targeted cancer therapies, including clinical-stage NXP800 and preclinical-stage NXP900.
Financial performance and position
Amounts below are in USD millions except per-share data. The company reported no product revenue; margins are therefore not applicable.
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Research and development expense | 4.52 | 4.16 | 8.83 | 8.40 |
| General and administrative expense | 1.42 | 0.51 | 3.63 | 2.23 |
| Operating loss | (5.94) | (4.67) | (12.46) | (10.63) |
| Net loss | (5.88) | (4.67) | (12.39) | (10.63) |
| Net loss per share | (0.42) | (1.04) | (1.03) | (2.54) |
| Operating cash used | Not provided quarterly | Not provided quarterly | (10.04) | (8.44) |
At September 30, cash and cash equivalents were $23.64 million; current assets were $24.87 million and current liabilities $4.49 million, implying working capital of about $20.37 million. Total liabilities were $4.49 million; the filing reports no debt balance. Accumulated deficit was $25.29 million. Financing activities provided $27.94 million during the first nine months of 2022, principally from the February IPO and July private placement.
Changes versus prior period
- Q3 net loss increased $1.21 million year over year; nine-month net loss increased $1.76 million.
- Q3 R&D expense rose $0.36 million, reflecting higher clinical activity, staffing and manufacturing, partly offset by lower licensing expense. Q3 G&A rose $0.91 million, including higher personnel and public-company insurance costs.
- Cash rose from $5.74 million at December 31, 2021 to $23.64 million at September 30, 2022, principally following the IPO and July financing. Series A preferred shares converted into common stock upon the IPO; common shares outstanding were 14,642,483 at September 30.
Outlook, risks and notable items
- Management said cash on hand was expected to fund planned operations for at least 12 months after the financial statements’ issuance. The company expects expenses to increase as it advances development and operates as a public company, and says additional capital will be needed to complete clinical development and pursue approvals.
- NXP800’s Phase 1 study began in December 2021; the FDA cleared its IND in June 2022. Nuvectis planned to investigate NXP800 in ovarian clear cell and endometrioid carcinoma and assess ARID1a deficiency as a selection marker. The company anticipated submitting an IND or equivalent for NXP900 in early 2023.
- Funding needs and development outcomes remain uncertain. Failure to obtain financing could force delays, reductions or termination of development. Additional equity financing may dilute shareholders; debt or partnering could impose restrictions or require concessions.
- License commitments include potential NXP800 milestones of up to $23.0 million before approval and a further $178 million in regulatory and commercial milestones, plus tiered royalties. NXP900 includes up to $46.0 million in pre-approval milestones and up to $279.5 million in regulatory and commercial milestones, plus royalties and a share of future fundraising subject to a $3.0 million cap. These contingent amounts are not recorded as liabilities unless applicable conditions are met. The company paid CRT a $1.0 million patient-enrollment milestone during Q3.
- No material legal proceedings or contingent liabilities were reported; management reported disclosure controls effective as of September 30, 2022. The filing states there were no material changes to previously disclosed risk factors.
Investor facts to verify
- Confirm the company’s current cash runway against actual clinical-trial spending and the timing and terms of any future financing.
- Track NXP800 Phase 1 safety, dose-escalation and enrollment progress, and the planned NXP900 IND submission.
- Review the scale and timing of license milestones, royalties and sponsored research commitments.
- Reconcile IPO proceeds disclosures: the filing gives net proceeds of $12.6 million in one discussion and approximately $13.1 million in another, with differing treatment or presentation of offering costs.
- Assess potential dilution from outstanding options, RSUs and warrants, including private-placement securities and future exercises.